Physician profile

Kyle James Cassas

Sports Medicine (Family Medicine) · Greenville, SC

NPI 1598718934

$1,439.24

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$707.25
Travel and Lodging$699.48

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Peerless Surgical INC. $580.34 2023
Arthrex, INC. $278.08 2023
Bioventus LLC $164.44 2021-2024 Exogen Ultrasound Bone Healing System, Durolane
Anika Therapeutics, INC. $150.83 2024 Integrity
Breg, INC $136.74 2023 Breg Vpulse, Plasmaflow, Polarcarewave
Nuvasive, INC. $112.61 2023 Xlif
Abbott Laboratories $16.20 2024 Proclaim

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kyle James Cassas

$1,439.24

in general payments reported 2019-2025

Years
2021-2024
Top company
Peerless Surgical INC.

https://glasscript.com/doctor/71532/kyle-james-cassas

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.